Discover a powerful, new (and somewhat unpopular) way to deal with anxiety and depression - without meditation, yoga, gratitude lists, pharmaceuticals and $49 Moleskine journals.
NYU will open a $10 million psychedelic research center to further its work in using psychedelic substances to treat mental health issues.
In this episode, we take a deep dive into Compass Pathways (CMPS), a psychedelic-medicines company aiming to treat depression with psilocybin.
To understand Compass Pathways (CMPS ), as a company and as an investment, you have to study 5 things:
What problem is Compass Pathways trying to solve?
CMPS’ clinical trial, treating depression with psilocybin
The founders and leaders of Compass Pathways
Compass’ Financials
Is CMPS stock a good investment for a retail investor?
As the psychedelic stocks sector takes off, Compass Pathways, alongside MindMed (MMED / MMEDF), looks poised to lead the pack. No other psychedelic-medicines company is as advanced in a clinical trial as is Compass Pathways (CMPS). CMPS has a phase 2b trial to test the effectiveness of psilocybin in treating Treatment-Resistant Depression could be game changing, and make for a great investment opportunity.
Let me know in the comments what you guys think. Is Compass Pathways a GOOD INVESTMENT? Will the CMPS stock skyrocket in 2021?
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
Resources:
https://compasspathways.com/
https://www.webmd.com/depression/understanding-depression-basics#1
https://www.psychiatry.org/patients-families/depression/what-is-depression
https://www.nimh.nih.gov/health/statistics/major-depression.shtml
https://www.webmd.com/depression/guide/depression-treatment-options#1
https://www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=Inotherwordsantidepressantsare,foundtobeequallyeffective
https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2222-4#:~:text=Treatmentresistantdepression(TRD),MDDpatientpopulation1
https://www.beckleyfoundation.org/psilocybin-for-depression-2
https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows
https://compasspathways.com/our-research/psilocybin-therapy/about-psilocybin-therapy/#from-subnav
https://psychedelicreview.com/person/ekaterina-malievskaia/
https://compasspathways.com/team-member/george-goldsmith/
https://compasspathways.com/team-member/lars-christian-wilde/
https://www.reuters.com/article/us-compass-pathways-ipo/peter-thiel-backed-compass-pathways-files-for-u-s-ipo-idUSKBN25O31T
https://www.globenewswire.com/news-release/2019/05/15/1825506/0/en/Anxiety-Disorder-and-Depression-Treatment-Market-To-Reach-USD-18-90-Billion-By-2026-Reports-And-Data.html
https://www.treehugger.com/facts-about-magic-mushrooms-4868810
https://psychedelicreview.com/person/ekaterina-malievskaia/
#CompassPathways #CMPS #PsychedelicStocks #MindMed #MMED #MMEDF #PsychedelicStocks #ThePsychedelicInvestor
In a world where wellness encompasses more than just physical health, The Body Workshop offers a unique platform for exploring the interconnectedness of mind, body, and spirit.
Mydecine Innovations Group says it has found 40 new compounds in at least 25 types of mushrooms with psychedelic and potentially therapeutic properties.
Host, David Flores, is joined by Joseph Caltabiano, the newly appointed Chairman and CEO of The Healing Realty Trust.
Weekly psychedelic news: Psychedelics could treat OCD, Novartis abandons study and Cybin Inc moves to acquire Small Pharma
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
